FDA CVM Vet-LIRN PROGRAM PROPOSAL FOR FOA PAR-23-202 “FDA Vet-LIRN Network Capacity-Building Project and Equipment Grants” ABSTRACT This proposal from the Ohio Department of Agriculture (ODA) is in response to Funding Opportunity Announcement (FOA) PAR-23-202 from the Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) Office of Applied Science's Veterinary Laboratory Investigation and Response Network (Vet-LIRN). The project is titled “FDA Vet-LIRN Cooperative Agreement with Ohio ADDL to support projects and work associated with One Health, animal food issues, antimicrobial resistance, and surge capacity testing”. This proposal from ODA’s Animal Disease Diagnostic Laboratory (ADDL) addresses the following key project areas: 1. Supporting the development, adaptation, or verification/validation of new methods associated with animal food issues or antimicrobial resistance. 2. Short-term monitoring efforts aligned with the CVM mission. 3. Supporting equipment for testing or developing tests associated with animal food-related issues or antimicrobial resistance, including those for emerging technologies. 4. Developing projects related to antimicrobial stewardship, in alignment with CVM's key initiatives in this area. 5. Contributing as part of Vet-LIRN's antimicrobial resistance (AMR) monitoring program, including sequencing isolates. 6. Supporting work associated with One Health, including emerging diseases such as COVID-19, when funding is available. 7. Support emergency surge capacity testing during large-scale animal food/feed emergency events requiring testing of implicated diagnostic or animal food samples The ADDL is also poised to address new developments in emerging regulatory sciences as well as urgent or novel areas for potential research. The laboratory’s certificate of AAVLD accreditation is provided as part of this proposal to showcase the laboratory’s ability to provide the capacity and capability to conduct the project. We are confident that we can meet the objectives of this project and look forward to the opportunity to work with the FDA.